Poulton Stuart bought KPTI
January 24, 2024 · Form 4 insider transaction
Poulton Stuart bought 13,333 shares of Karyopharm Therapeutics Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1 day after the transaction.
Footnotes
Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of a certain clinical milestone, as certified by the issuer's compensation committee on January 24, 2024. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs will vest on February 28, 2024, the first anniversary of the grant date, subject to continued employment through such vesting date.